BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17409902)

  • 1. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging.
    Erasmus JJ; Munden RF; Truong MT; Ho JJ; Hofstetter WL; Macapinlac HA; Correa AM; Wu TT; Bruzzi JF; Marom EM; Sabloff BS; Ajani JA; Komaki R; Liao Z; Lee JH; Fukami N; Bresalier R; Swisher SG
    J Thorac Oncol; 2006 Jun; 1(5):478-86. PubMed ID: 17409902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma.
    Yen TJ; Chung CS; Wu YW; Yen RF; Cheng MF; Lee JM; Hsu CH; Chang YL; Wang HP
    Dis Esophagus; 2012 Jan; 25(1):40-7. PubMed ID: 21595776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
    J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
    Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
    Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
    Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus.
    Roedl JB; Halpern EF; Colen RR; Sahani DV; Fischman AJ; Blake MA
    Mol Imaging Biol; 2009; 11(1):54-60. PubMed ID: 18769974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma.
    Kato H; Kuwano H; Nakajima M; Miyazaki T; Yoshikawa M; Ojima H; Tsukada K; Oriuchi N; Inoue T; Endo K
    Cancer; 2002 Feb; 94(4):921-8. PubMed ID: 11920459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
    Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
    Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan.
    Huang JW; Yeh HL; Hsu CP; Lu YY; Chuang CY; Lin JC; Lin JF; Chang CF
    J Chin Med Assoc; 2015 Apr; 78(4):229-34. PubMed ID: 25557468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma.
    Konski A; Doss M; Milestone B; Haluszka O; Hanlon A; Freedman G; Adler L
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1123-8. PubMed ID: 15752892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal imaging of esophagus and cardia cancer before and after treatment.
    Fiore D; Baggio V; Ruol A; Bocus P; Casara D; Corti L; Muzzio PC
    Radiol Med; 2006 Sep; 111(6):804-17. PubMed ID: 16896560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy.
    Kalff V; Ware R; Heriot A; Chao M; Drummond E; Hicks RJ
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):60-6. PubMed ID: 18922649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma.
    Salahudeen HM; Balan A; Naik K; Mirsadraee S; Scarsbrook AF
    Clin Radiol; 2008 Jul; 63(7):765-73. PubMed ID: 18555034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.